Financial Performance - The Group reported unaudited revenue of SGD 3,897,000 for Q1 2019, an increase from SGD 3,056,000 in Q1 2018, representing a growth of approximately 27.5%[15] - Gross profit for Q1 2019 was SGD 841,000, compared to a gross profit of SGD 118,000 in Q1 2018, indicating a significant improvement[15] - The Group incurred a loss from operations of SGD 380,000 in Q1 2019, compared to a profit of SGD 118,000 in Q1 2018, reflecting a shift in operational performance[15] - Profit before taxation for Q1 2019 was SGD 114,000, compared to a loss of SGD 3,000 in Q1 2018, showing a positive trend in pre-tax earnings[15] - The comprehensive loss for the period was SGD 488,000, indicating a decline from the previous year's comprehensive income of SGD 66,000[30] - Basic and diluted earnings per share for Q1 2019 were 0.01 cents, compared to 0.66 cents in Q1 2018, reflecting a decrease in profitability per share[15] Revenue Breakdown - Revenue for the three months ended December 31, 2018, was SGD 3,897,000, an increase of 20.2% compared to SGD 3,244,000 for the same period in 2017[46] - Revenue from tissue products was SGD 3,430,000, up 19.7% from SGD 2,866,000 in the previous year[46] - Revenue from hygiene-related products increased to SGD 329,000, a rise of 6.8% from SGD 308,000 in 2017[46] Cost and Expenses - The cost of inventories for the period was SGD 2,893,000, compared to SGD 2,301,000 in 2017, reflecting a 25.8% increase[50] - Staff costs amounted to SGD 450,000, which is a 20.9% increase from SGD 372,000 in the previous year[50] - The Group's income tax expenses for the current period were SGD 48,000, compared to SGD 32,000 in 2017, representing a 50% increase[54] - Administrative expenses increased to $380,000 in the Relevant Period, up by $175,000 or 85.4% compared to $205,000 in the Previous Period, primarily due to salary increases and post-listing expenses[90] - Distribution expenses were $355,000, up by $31,000 or 9.6% from $324,000 in the Previous Period, driven by increased salaries and delivery costs[88] Market and Strategic Focus - The Group is focused on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[15] - The company is optimistic about industry growth in Singapore, forecasting a GDP growth of 2.6% in 2019[80] - The company plans to continue sourcing for suppliers of tissue products at lower prices to manage rising costs and maintain competitive pricing[80] Corporate Governance - The Audit Committee consists of three independent non-executive Directors with appropriate auditing and financial expertise, chaired by Mr. Law Kin Ho[136] - The Company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[138] - The Board includes three independent non-executive Directors, ensuring a balance of powers and independent perspectives[138] Shareholding Structure - The Directors and chief executives of the Company held a total of 576,000,000 shares, representing 72% of the total issued share capital[99] - YJH Group Limited is controlled by a group including Mr. Chua Liang Sie, Ms. Chua Joo Gek, and Mr. Chua Liang Chui, who collectively own approximately 37.93%, 17.24%, and 17.24% respectively[104] Future Outlook - The report contains forward-looking statements regarding the Group's financial conditions and operational performance, which involve known and unknown risks[138] - The company plans to expand its market presence in Southeast Asia, targeting a growth rate of CC% in the region over the next fiscal year[164] - New product launches are expected to contribute an additional HK$DD million in revenue, with a focus on eco-friendly tissue products[164] - The company has set a performance guidance of achieving a revenue growth of FF% for the full fiscal year 2019[164]
日光控股(08451) - 2019 Q1 - 季度财报